DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Phase 4

Not yet recruiting

Conditions: Relapsed/Refractory AML

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: G-CSF
Drug: Venetoclax

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 172

Registration Number: NCT06763666

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2025-03-20

Last Posted Date: 2025-03-20

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 30

Registration Number: NCT06885814

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, GuangZhou, Guangdong, China

Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis

Completed

Conditions: 28-day Mortality

Interventions: Drug: Human serum albumin injection

First Posted Date: 2025-03-13

Last Posted Date: 2025-03-13

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 180

Registration Number: NCT06874634

Locations: 🇨🇳
Department of Critical Care Medicine, Guangzhou, Guangdong, China

Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma

Recruiting

Conditions: Hepatocellular Carcinoma
Radiotherapy
Treatment Outcome
Biomarkers
Sphingolipids

First Posted Date: 2025-03-07

Last Posted Date: 2025-03-12

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 260

Registration Number: NCT06864221

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods

Not yet recruiting

Conditions: Inflammatory Bowel Diseases

First Posted Date: 2025-02-27

Last Posted Date: 2025-02-27

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 60

Registration Number: NCT06849739

Locations: 🇨🇳
NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

Not Applicable

Not yet recruiting

Conditions: Gastric Lesion
Gastritis
Upper Gastrointestinal Bleeding (UGIB)
Gastric Dysplasia
Gastric Ulcer
Gastric Neoplasms

First Posted Date: 2025-02-27

Last Posted Date: 2025-02-27

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 482

Registration Number: NCT06848400

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions: Drug: Toripalimab (240mg day1, Q3W*3cycle)

First Posted Date: 2025-02-25

Last Posted Date: 2025-04-16

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 34

Registration Number: NCT06843889

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Baiyun District, China

Pharmacokinetic Study of Oligonucleotides in Maixuekang Capsules

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Maixuekang capsule

First Posted Date: 2025-02-12

Last Posted Date: 2025-02-12

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 12

Registration Number: NCT06823895

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China

Effect of Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Surgery (ELEMENT)

Not Applicable

Recruiting

Conditions: Pain, Postoperative
Esketamine
Delirium in Old Age
Delirium, Postoperative
Anesthesia
Cognitive Dysfunction
Non-cardiac Surgery

Interventions: Drug: Esketamine
Drug: Normal saline

First Posted Date: 2025-02-10

Last Posted Date: 2025-04-27

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 1670

Registration Number: NCT06817239

Locations: 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
The First Affiliated Hospital of JiNan University, Guangzhou, Guangdong, China

and more 3 locations

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Phase 3

Recruiting

Conditions: Newly Diagnosed Acute Myeloid Leukemia With High Risk

Interventions: Drug: Standard Chemotherapy
Drug: HVA
Drug: VA

First Posted Date: 2025-02-06

Last Posted Date: 2025-02-06

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 876

Registration Number: NCT06810791

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy